Smartest Doc
External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy
Pancreas, 07/06/2012
Clinical Article
Haas M et al. – Both Asian indices may not be suitable for defining different prognostic subgroups for a white population with advanced pancreatic cancer.
Methods- A score was calculated in patients treated with frontline therapy derived from the factors Eastern Cooperative Oncology Group Performance Status, localization of primary tumor, and C-reactive protein level according to Sawaki and from the factors Eastern Cooperative Oncology Group Performance Status, pretreatment carcinoembryonic antigen, and presence/absence of distant metastasis following Ishii.
- For analysis, the Kaplan-Meier method and the log-rank test were used.
- An analysis of the Brier score was performed to determine how the prediction error was reduced by the introduction of prognostic factors.
- For the Sawaki and Ishii score, 112 and 105 complete cases were available, respectively.
- Based on the 3 prognostic categories according to the Sawaki score, median overall survival was 12.3, 9.9, and 5.9 months, respectively (not statistically significant).
- By adapting the Ishii score to the population, 93% of the patients were allocated to the subgroup with “good” and only 7% to the subgroup with “intermediate” prognosis.
- Corresponding median OS was 10.5 and 3.8 months, respectively (P = 0.0035).
